Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 3/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.31 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.31 |
| ▸ | PTAFR | P25105 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883262 | 0.86 | TYMS (0.35) | TYMSSRD5A1SRD5A2 | |
| SCHEMBL2065597 | 0.86 | TYMS (0.35) | TYMSSRD5A1SRD5A2 | |
| SCHEMBL13746544 | 0.86 | TYMS (0.35) | TYMSSRD5A1SRD5A2 | |
| SCHEMBL2065596 | 0.86 | TYMS (0.35) | TYMSSRD5A1SRD5A2 | |
| SCHEMBL3425525 | 0.85 | HTR2C (0.36) | TYMSSRD5A1SRD5A2 | |
| SCHEMBL10201478 | 0.85 | HTR2C (0.36) | TYMSSRD5A1SRD5A2 | |
| SCHEMBL10232542 | 0.85 | HTR2C (0.36) | TYMSSRD5A1SRD5A2 | |
| SCHEMBL13747270 | 0.85 | HTR2C (0.36) | TYMSSRD5A1SRD5A2 | |
| SCHEMBL10182594 | 0.83 | TYMS (0.39) | TYMSSRD5A1SRD5A2PARP10PARP11 | |
| SCHEMBL750120 | 0.78 | HCRTR1 (0.41) | TYMSSRD5A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245027-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-04-25 | — | — | EP | disclosed |
| US-8147818-B2 | inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | TYMS 2963/4885SRD5A1 2359/4885SRD5A2 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.